Qiagen NV (NYSE:QGEN) saw a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 5,380,000 shares, an increase of 19.8% from the January 15th total of 4,490,000 shares. Approximately 2.5% of the shares of the company are short sold. Based on an average daily trading volume, of 2,900,000 shares, the short-interest ratio is currently 1.9 days.
QGEN has been the subject of several analyst reports. TheStreet downgraded shares of Qiagen from a “b-” rating to a “c+” rating in a report on Friday, October 18th. Stifel Nicolaus initiated coverage on shares of Qiagen in a report on Thursday, November 14th. They issued a “hold” rating and a $33.00 price objective for the company. Piper Sandler raised their price objective on shares of Qiagen from to and gave the stock a “neutral” rating in a report on Wednesday, February 5th. Barclays reaffirmed a “neutral” rating on shares of Qiagen in a report on Wednesday, February 5th. Finally, Citigroup initiated coverage on shares of Qiagen in a report on Monday, January 6th. They issued a “neutral” rating and a $35.00 price objective for the company. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and seven have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $36.23.
NYSE:QGEN traded up $0.41 during trading hours on Friday, hitting $37.14. The stock had a trading volume of 1,039,996 shares, compared to its average volume of 2,501,974. The company has a 50 day simple moving average of $34.57 and a two-hundred day simple moving average of $35.00. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.65 and a quick ratio of 1.47. Qiagen has a one year low of $25.04 and a one year high of $43.16. The firm has a market capitalization of $8.36 billion, a price-to-earnings ratio of -185.70, a P/E/G ratio of 2.35 and a beta of 0.92.
Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Tuesday, February 4th. The company reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.04. Qiagen had a negative net margin of 2.72% and a positive return on equity of 13.00%. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $408.28 million. During the same period last year, the firm earned $0.40 EPS. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Equities research analysts anticipate that Qiagen will post 1.52 earnings per share for the current year.
A number of large investors have recently made changes to their positions in QGEN. Nisa Investment Advisors LLC boosted its holdings in Qiagen by 23.8% in the 3rd quarter. Nisa Investment Advisors LLC now owns 82,061 shares of the company’s stock valued at $2,706,000 after purchasing an additional 15,796 shares during the period. Envestnet Asset Management Inc. lifted its holdings in shares of Qiagen by 14.0% during the 3rd quarter. Envestnet Asset Management Inc. now owns 50,850 shares of the company’s stock worth $1,674,000 after acquiring an additional 6,251 shares during the last quarter. Cambiar Investors LLC lifted its holdings in shares of Qiagen by 11.8% during the 3rd quarter. Cambiar Investors LLC now owns 145,895 shares of the company’s stock worth $4,810,000 after acquiring an additional 15,416 shares during the last quarter. Stephens Investment Management Group LLC lifted its holdings in shares of Qiagen by 18.5% during the 3rd quarter. Stephens Investment Management Group LLC now owns 138,967 shares of the company’s stock worth $4,582,000 after acquiring an additional 21,695 shares during the last quarter. Finally, Stephens Inc. AR lifted its holdings in shares of Qiagen by 61.6% during the 3rd quarter. Stephens Inc. AR now owns 8,397 shares of the company’s stock worth $277,000 after acquiring an additional 3,201 shares during the last quarter. 62.66% of the stock is owned by hedge funds and other institutional investors.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Further Reading: Risk Tolerance
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.